Investigational Drug Information for SGN-CD19A
✉ Email this page to a colleague
What is the development status for investigational drug SGN-CD19A?
SGN-CD19A is an investigational drug.
There have been 4 clinical trials for SGN-CD19A.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2016.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, B-Cell, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are Seagen Inc., Seattle Genetics, Inc., and [disabled in preview].
There are ninety US patents protecting this investigational drug and zero international patents.
Summary for SGN-CD19A
| US Patents | 90 |
| International Patents | 1,341 |
| US Patent Applications | 373 |
| WIPO Patent Applications | 314 |
| Japanese Patent Applications | 86 |
| Clinical Trial Progress | Phase 1 (2016-08-01) |
| Vendors | 15 |
Recent Clinical Trials for SGN-CD19A
| Title | Sponsor | Phase |
|---|---|---|
| Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | Seagen Inc. | Phase 2 |
| Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | Seattle Genetics, Inc. | Phase 2 |
| Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma | Seagen Inc. | Phase 2 |
Clinical Trial Summary for SGN-CD19A
Top disease conditions for SGN-CD19A
Top clinical trial sponsors for SGN-CD19A
US Patents for SGN-CD19A
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SGN-CD19A | ⤷ Sign Up | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | Fundacio Institut de Recerca Biomedica (IRB Barcelona) (Barcelona, ES) Institucio Catalana de Recerca I Estudis Avancats (Barcelona, ES) | ⤷ Sign Up |
| SGN-CD19A | ⤷ Sign Up | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | ⤷ Sign Up |
| SGN-CD19A | ⤷ Sign Up | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (Cambridge, MA) | ⤷ Sign Up |
| SGN-CD19A | ⤷ Sign Up | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | ⤷ Sign Up |
| SGN-CD19A | ⤷ Sign Up | Bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | ⤷ Sign Up |
| SGN-CD19A | ⤷ Sign Up | NAMPT and ROCK inhibitors | AbbVie Inc. (North Chicago, IL) | ⤷ Sign Up |
| SGN-CD19A | ⤷ Sign Up | Combination therapy for inducing immune response to disease | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SGN-CD19A
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SGN-CD19A | Australia | AU2013273242 | 2032-06-06 | ⤷ Sign Up |
| SGN-CD19A | Australia | AU2019204269 | 2032-06-06 | ⤷ Sign Up |
| SGN-CD19A | Brazil | BR112014030750 | 2032-06-06 | ⤷ Sign Up |
| SGN-CD19A | Canada | CA2875918 | 2032-06-06 | ⤷ Sign Up |
| SGN-CD19A | China | CN104603288 | 2032-06-06 | ⤷ Sign Up |
| SGN-CD19A | Denmark | DK2859120 | 2032-06-06 | ⤷ Sign Up |
| SGN-CD19A | European Patent Office | EP2859120 | 2032-06-06 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
